Incyte (INCY) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY)

INCY 104.09

-1.3%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (2867)	6/2/2013 2:24:09 PM
From: scaram(o)uche	Read Replies (1) of 3202

re. 360...... “We look forward to seeing results of the randomized Phase I/II study underway in advanced melanoma in combination with ipilimumab....." finance.yahoo.com and on-topic but off-topic..... finance.yahoo.com Bristol-Myers Squibb Announces Phase 1 Results from First Trial Combining Immune Checkpoint Inhibitors, Investigational Agent Nivolumab and Yervoy® (ipilimumab), in Patients with Advanced Melanoma •53% response rate observed in patients receiving 1 mg/kg nivolumab plus 3 mg/kg Yervoy concurrently (n= 9 of 17), the dose used in the Phase 3 trial; of these responders all experienced at least 80% tumor shrinkage within 12 weeks •Grade 3-4 treatment-related adverse events occurred in 53% of patients on the concurrent-regimen and 18% of patients on the sequenced-regimen •Data published today in New England Journal of Medicine •Estimated survival data from this Phase 1 trial presented at 49th annual meeting of the American Society of Clinical Oncology •Phase 3 trial of nivolumab in combination with Yervoy in advanced melanoma underway

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next